Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
21°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
8.770
-0.160 (-1.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
March 10, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Upcoming March Conferences
February 25, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Pricing of Upsized Public Offering of Common Stock
January 29, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Proposed Public Offering of Common Stock
January 29, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
Immunome, Inc.
Via
Business Wire
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
January 07, 2025
From
Hummingbird Bioscience
Via
GlobeNewswire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
October 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
October 18, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Completion of Purchase of Assets from Atreca
May 20, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 17, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 2024 Bank of America Healthcare Conference
May 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
May 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
April 25, 2024
From
Immunome
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.